Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
John Hilton, Carol Stober, Sasha Mazzarello, Lisa Vandermeer, Dean Fergusson, Brian Hutton, Mark Clemons, John Hilton, Carol Stober, Sasha Mazzarello, Lisa Vandermeer, Dean Fergusson, Brian Hutton, Mark Clemons
Abstract
Introduction: Despite the importance of chemotherapy in the treatment of early stage triple negative breast cancer (TNBC), no one optimal regimen has been identified. We conducted a pilot trial comparing outcomes for the three most commonly used chemotherapy regimens to assess the feasibility of conducting a larger definitive trial.
Methods: Using integrated consent, newly diagnosed TNBC patients were randomised to one of three standard regimens: dose-dense doxorubicin-cyclophosphamide then paclitaxel, doxorubicin-cyclophosphamide then weekly paclitaxel or 5-FU-epirubicin-cyclophosphamide then docetaxel. Feasibility endpoints included; physician engagement, accrual rates, physician compliance and patient satisfaction with the integrated consent model. Our anticipated pilot trial sample size was 35 randomised patients in one year.
Results: Between August 30th, 2016 and January 31st 2017, 2 patients met eligibility and were randomised. A survey of 10 participating oncologists was performed to identify potential strategies to enhance accrual. Most investigators (9/10) believed that the best regimen for TNBC was unknown, and 4/10 felt this was a pressing clinical question. Physicians' responses suggested that poor accrual was due to: a lack of interest in some study arms as oncologists already had a preferred regimen (4/10) and concerns about trial demands in busy clinics (3/10). The pilot feasibility endpoints were not met and the study was closed.
Conclusions: Despite initial interest in the trial question and multiple investigators agreeing to approach patients, this trial failed to meet feasibility endpoints. The reasons for poor accrual were multiple and require further evaluation if this important patient-centred question is to be answered.
Trial registration: ClinicalTrials.gov NCT02688803.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(16):2784–95.
- Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007;25(1):118–45.
- Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463–72. 10.1002/cncr.27581
- Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research: BCR. 2013;15(5):R88 10.1186/bcr3484
- Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer causes & control: CCC. 2009;20(7):1071–82.
- Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Jama. 2006;295(14):1658–67. 10.1001/jama.295.14.1658
- Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Pena-Curiel O, Baez-Revueltas B, et al. Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast cancer research and treatment. 2014;146(3):567–72. 10.1007/s10549-014-3033-4
- Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, et al. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncology letters. 2014;7(3):866–70. 10.3892/ol.2014.1782
- Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clinical breast cancer. 2009;9(1):29–33. 10.3816/CBC.2009.n.005
- Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, et al. Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2017.
- Amir E, Ocana A, Freedman O, Clemons M, Seruga B. Chemotherapy: dose-dense treatment for triple-negative breast cancer. Nature reviews Clinical oncology. 2010;7(2):79–80. 10.1038/nrclinonc.2009.231
- Hilton J, Mazzarello S, Fergusson D, Joy AA, Robinson A, Arnaout A, et al. Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer. J Oncol Pract. 2016.
- . Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) (OTT15-04) 2017 [Available from: .
- Kim SY, Miller FG. Informed consent for pragmatic trials—the integrated consent model. N Engl J Med. 2014;370(8):769–72. 10.1056/NEJMhle1312508
- Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, et al. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer. 2016;24(8):3633–50. 10.1007/s00520-016-3256-5
- Arnaout A, Kuchuk I, Bouganim N, Pond G, Verma S, Segal R, et al. Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study. Curr Oncol. 2016;23(3):e276–9. 10.3747/co.23.2394
Source: PubMed